ArticleClinical epidemiology2025
Modelling Asthma Treatment Dynamics: Insights from the g-Formula.
Article in Clinical epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The g-formula offers a promising approach to analyze long-term dynamic asthma treatment trajectories. This study investigates whether the g-formula can simulate real-world asthma treatment trajectories and predicts subgroup differences in switching behavior. Patients and Methods: This retrospective cohort study identified individuals aged 16- to 45 years who initiated inhaled asthma medication in the Netherlands between 1994 and 2021, from the IADB.nl pharmacy dispensing database. We used the g-formula combined with logistic regression to predict treatment trajectories and their associations with various patient characteristics, such as age, sex, chronic drug treatment for atopic diseases (ATD), cardiovascular diseases (CVD), thyroid diseases, arthritis, diabetes, gastroesophageal reflux disease (GERD), mental health problems (MHP), and immunosuppressants. Results: The simulations predicted 76% of individuals to switch treatment, on average 2.3 times, with the first switch occurring on average after 8.3 months, which agrees with the real-world observations (77%, 2.3 times and 7.9 months, respectively). Fewer 45-year-olds switched treatment compared to 16-year-olds (74% vs 78%, p < 0.001), but they switched earlier (8.1 vs 8.6 months, p < 0.001) and more frequently (2.4 vs 2.3 times, p < 0.001). Women were more likely to switch compared to men. Patients with ATD, CVD, MHP, or GERD switched significantly less often (p < 0.05). Conclusion: The g-formula effectively simulates asthma treatment trajectories and found higher age, male sex, ATD, CVD, MHP, and GERD to decrease overall switching behavior. These patients might benefit from earlier intervention or closer monitoring to reduce delays in treatment progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.